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Author Manuscript Published OnlineFirst on April 3, 2012; DOI: 10.1158/1078-0432.CCR- The mammalian target of rapamycin (mTOR) performs an important role in the regulation of cellular function. In renal cell carcinoma, inactivation of von HippelLindau tumor-suppressor gene (VHL), a common molecular abnormality in renal cancer, results in abnormal accumulation of hypoxia-inducible factor (HIF), mediated by mTOR, that drives cellular growth and angiogenesis (1) (2) (3) (4) (5) . Emerging evidence suggests that mTOR also plays a central role in sensing nutrient availability in the cell, particularly in regard to lipid and glucose metabolism (6) (7) (8) . Under nutrient-poor conditions in a normal cellular environment, downstream mTOR activation is attenuated. However, in cancer cells, aberrantly high mTOR activity leads to growth and proliferation, even in nutrient poor conditions (9-11).
Temsirolimus, an mTOR inhibitor, is an effective treatment of renal cancer. In a randomized phase III trial of patients with metastatic renal cell carcinoma and multiple risk factors for short survival, treatment with temsirolimus was associated with improved overall survival (OS) and progression-free survival (PFS), compared with interferon alfa2a (12) . Better PFS was also reported in a placebo-controlled randomized trial of patients with advanced renal cell carcinoma treated with everolimus, another mTOR inhibitor, after failure of prior vascular endothelial growth factor-targeted therapy (13) .
Increases in serum cholesterol, triglyceride, and glucose with mTOR inhibitors have been commonly observed in clinical trials (12) (13) (14) (15) , and represent adverse events that could reflect the mechanism of action of this class of drugs. Therefore, in this study, we investigated whether changes in cholesterol, triglyceride and glucose levels, compared 
Patients and Method
The Global Advanced Renal Cell Carcinoma Trial (ClinicalTrials.gov number, NCT00065468) was a 3-arm phase III trial in which patients with advanced renal-cell carcinoma with an intermediate-risk or poor-risk classification were randomly assigned to first-line therapy of interferon alfa-2a (starting dose of 3 million U given subcutaneously 3 times per week), temsirolimus (25 mg intravenously weekly), or combination interferon alfa-2a and temsirolimus (starting dose of interferon 3 million U given subcutaneously 3 times per week and temsirolimus 15 mg intravenously weekly) (12) . The disease was assessed every 8 weeks by the Response Evaluation Criteria in Solid Tumors (RECIST) (16) , and patients continued on treatment until disease progression or symptomatic deterioration or intolerable adverse events, as defined by National Cancer Institute Common Terminology Criteria of Adverse Events (NCI CTCAE v.3.0). Eligible patients had stage IV or recurrent renal-cell carcinoma, a Karnofsky performance score of 60 or higher, no previous systemic therapy, adequate bone marrow, hepatic, and renal function. Patients in this study were also required to have fasting total cholesterol level ≤9.1 mmol/L (350 mg/dL) and triglyceride ≤4.5 mmol/L (400 mg/dL), but no restriction on fasting blood glucose level. At least three of the following six predictors of poor prognosis were required: serum lactate dehydrogenase level of more than 1.5 times the upper limit of the normal range, hemoglobin level below the lower limit of the normal range; corrected serum calcium level of more than 2.5 mmol/L (10 mg/dL), <1 year from initial diagnosis of renal-cell carcinoma to randomization, Karnofsky performance score of 60 or 70, and metastases in multiple organs. All patients gave informed consent. The primary endpoint was OS, and secondary endpoints included PFS, tumor response, and clinical benefit. The results of this trial have been published (12) .
Cholesterol, triglyceride and glucose measurements during trial
Cholesterol, triglycerides and glucose were each measured at baseline prior treatment.
Measurements of these biomarkers were repeated every two weeks when patients were undergoing treatment in the trial. Change in the biomarker is defined as the difference between biomarker measurement during treatment and its baseline value.
The value of change in serum cholesterol, triglyceride and glucose concentrations as predictors of temsirolimus efficacy
The objective of this study was to explore the potential value of change in serum cholesterol, triglyceride, and glucose concentrations as predictors of treatment advantage of temsirolimus compared to interferon on OS and PFS. Serum cholesterol, triglyceride, and glucose concentrations were modelled as time-varying covariates over the entire course of treatment. Changes in these biomarkers from pretreatment baseline readings were examined. The primary comparison made was between patients treated with temsirolimus only and those treated with interferon only after adjusting for baseline and on-study biomarker values. Variation in the effect of treatment across different randomization strata was also examined: we compared regional differences between patients treated in the United States of America (USA) and patients treated in the non- USA countries, and between patients with and without prior nephrectomy. Patients treated with temsirolimus and those treated with a combination of interferon and temsirolimus were compared in sensitivity analyses.
Statistical methods
Baseline patient and disease characteristics were compared by t tests for continuous variables and χ 2 tests for categorical variables. The differences between treatment groups in the changes in each biomarker relative to baseline were assessed by using generalized estimating equations (GEE), with an autoregressive correlation structure to account for the multiple measurements on each patient (17) . The estimated marginal mean using the regression coefficients and the 95% confidence intervals from the GEE model are presented for each treatment group. OS was defined as the time from randomisation to death from any cause. PFS was defined as the time from randomisation to first documented progression as determined by the site investigators' assessment or death. The Global Advanced Renal Cell Carcinoma Trial prespecified the following factors as potentially important baseline characteristics which might impact on PFS and OS: age, sex, geographic region, nephrectomy status, tumor histologic type, time from metastasis to randomization, Karnofsky performance score, and levels of hemoglobin, serum lactate dehydrogenase, and corrected serum calcium. These factors are adjusted for in multivariable Cox proportional-hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the baseline and time-varying covariates (18) . Extended Kaplan-Meier curves were used to illustrate the effect of time-varying covariates from proportional-hazards models (19 according to their repeated measurements of these biomarkers during the entire study (the values used for the time-varying covariate in the proportional hazards model collapsed into categories according to the median). The number of patients in each stratum is updated at each event time so patients can be counted in different strata as their biomarkers change over time.
We also performed landmark analyses to reduce possible confounding by time on treatment by assessing the impact of change in each individual biomarker at various landmark times on survival outcomes. Patients with early disease progression / deaths or patients lost to follow-up before the landmark times were excluded. Change in the biomarker was defined as the difference in the last reading for the biomarker obtained at landmark time from baseline. For these analyses, PFS and OS times were measured from the landmark times to these survival outcomes. Multivariable Cox proportional-hazards models were used to estimate HR and 95% CI for treatment effect adjusted for change in biomarker. The landmark times at 1 month and 2 months post-randomisations were explored.
All P values were two-sided, CIs were at the 95% level, and no adjustments were made for multiple comparisons.
Research. 
Results
The primary analysis population was 416 patients (207 in the interferon alfa-2a group, 209 in the temsirolimus group) with a median follow-up of 17.9 months (range 0.3-27.5). Table 1 displays the baseline patient and disease characteristics by treatment group, which were well balanced. There was no significant difference in the baseline serum cholesterol (P=.63), triglyceride (P=.11), or glucose (P=.60) measurements between the two treatment groups.
At baseline, serum cholesterol, triglyceride and glucose measurements were available in 81%, 98% and 98% of the total patients respectively. At two and four months postrandomisation, 70% and 42% of the total patients had serum cholesterol, triglyceride and glucose measurements performed respectively.
Effect of treatment on the biomarkers
During the study, serum cholesterol increased significantly from baseline in the temsirolimus group, with a mean rise of 0.95 mmol/L [37 mg/dL] (P<.0001) ( Figure 1A ).
In the interferon group, serum cholesterol did not change significantly from baseline during the study; mean change in cholesterol from baseline was -0.07 mmol/L [3 mg/dL] (P=.19). Serum triglyceride and glucose were both significantly increased from baseline for the temsirolimus and the interferon groups; the changes in these biomarkers are summarized in Figure 1B and 1C respectively. Figure 2B ). The log-rank test of equality of these four curves was also significant (P<.0001).
Baseline serum triglyceride and glucose did not predict PFS or OS in univariate or multivariate analyses (Table 2 ). During the study period, increase in serum triglyceride from baseline was associated with a reduced risk of disease progression and death in univariate or multivariate analyses (Table 3) . However, increase in serum glucose from baseline during the study period was not associated with a reduced risk of disease progression or death in multivariate analyses (Table 3) .
Change in biomarkers as a predictor of the effect of treatment on survival
In multivariable analyses of treatment with adjustment for change in cholesterol and baseline cholesterol level, temsirolimus (compared with interferon) no longer improved survival outcomes; for OS, adjusted HR (temsirolimus versus interferon) =1.14 (95% CI, 0.85 to 1.53; P=.37), and for PFS, adjusted HR (temsirolimus versus interferon) =0.88 (95% CI, 0.67 to 1.15; P=.35). Therefore, changes in cholesterol appear to account for most of the advantageous effect of temsirolimus on OS and PFS ( Figure 3 and Table 4 ).
When the association between treatment and clinical outcome was adjusted individually for serum triglyceride or for glucose, the relative treatment advantage of temsirolimus over interferon remained statistically significant for PFS and did not change substantially from the unadjusted estimate for OS ( Figure 3 and Table 4 ). Therefore, the treatment effect of temsirolimus was largely independent of changes in serum triglyceride or glucose. . 
Regional variations in
On study statin treatment was equally common in USA and non-USA countries (5.7% vs 6.1%, P =.88). When the analyses were repeated to account for on-study statin treatment, similar results were obtained (not shown).
When the analyses were repeated for patients who had nephrectomy compared with those without nephrectomy, similar results were obtained with smaller cholesterol rise in the non-nephrectomy stratum also associated with a smaller treatment effect.
Impact of on-study statin treatment, change in serum cholesterol and the effect of treatment
Significantly more patients were treated with statin in the temsirolimus group during the study as compared to the interferon group (11.0% vs 1.0%, P <.0001). On-study statin 
Discussion
The Global Advanced Renal Cell Carcinoma Trial demonstrated temsirolimus was associated with improved survival compared with interferon alfa-2a (12) . Here, we demonstrate in this study, an increase in cholesterol was associated with longer survival and predicted temsirolimus efficacy. Temsirolimus was associated with a larger increase in serum cholesterol as compared to interferon. Amongst the patients treated with temsirolimus, those surviving longer were also observed to have larger increase in cholesterol. Moreover, when the effect of treatment on serum cholesterol change was accounted for in multivariable analyses, no additional temsirolimus advantage over Nevertheless, these in vitro data are supported by in vivo and clinical studies. In guinea pigs, rapamycin alters the insulin signaling pathway, resulting in elevated serum triglyceride and glucose (25) . In a phase I study of deferolimus, maximum change in serum cholesterol in the first two cycles was significantly associated with a response to treatment (15) . In a phase II study of temsirolimus, elevated serum lipids during the first two cycles of treatment was also significantly associated with radiographic response (26) .
Despite preclinical and some early-phase clinical trial data, our study based on a single large phase III study shows that serum cholesterol, but not triglyceride or glucose, is a potential biomarker for temsirolimus efficacy. It remains unclear why serum triglyceride and glucose do not show the same attributes. This may be related to the stringent requirement and other limitations of the statistical approach used in the present study (27) (28) (29) . A recently developed meta-analytic approach, using data from many randomized trials, to directly measure the association between the treatment effects on a surrogate and the true clinical survival endpoint, has been proposed as an alternative approach for surrogate endpoint analysis (30) (31) (32) . Such an approach has been performed to demonstrate that disease-free survival is a valid surrogate endpoint for overall survival in colorectal cancer (33, 34) .
The main strengths of our study include the large sample size, the availability of survival data, regular repeated measurements of cholesterol, triglycerides, and glucose, and treatment superiority in the experimental arm allowing for analysis of treatment-bybiomarker interaction. Differences in the outcomes allowed for direct comparisons across the three different biomarkers; cholesterol, but not glucose or triglycerides, was linked to survival benefit. Furthermore, the observation of increased cholesterol and improved survival was consistent across all study stratification variables.
This study has a number of limitations. First, this analysis was conducted post-hoc using available trial data and therefore should be regarded as hypothesis-generating for future studies, rather than definitive. Second, landmark analyses to assess the impact of early change in cholesterol on survival outcomes were limited because fewer patients were available, and fewer outcome events were documented after the landmark time of 2 months which coincides with the maximal rise in cholesterol ( Figure 1A) . However, the results of landmark analyses at 1 month give similar qualitative conclusions as the timevarying Cox proportional-hazards analyses (Figure 3 ) which assess cholesterol change throughout the trial to provide greater power to detect its impact on survival. Finally, serum cholesterol, triglyceride and glucose were measured on all trial subjects as part of the ARCC trial protocol to monitor for potential toxicities from treatment. The laboratories used current standard protocols and quality control procedures for these routine assays. However, not all samples collected were fasting specimens which might impact on the reproducibility of results. As the primary objective of the ARCC trial was not to investigate the impact of cholesterol, triglyceride and glucose changes on clinical outcomes, the trial protocol did not specify quantitative methods and reproducibility assessments, and this information was not collected to allow a complete assessment and reporting of assay methods to address the REMARK criteria (35).
This study is not sufficiently powered to investigate whether treatment with statins interacts with temsirolimus-mediated inhibition of mTOR as only 25 patients received statins during the study. Other studies have demonstrated that statins appear to reduce mTOR activation and improved chemotherapy sensitivity (36, 37) . It remains speculative whether statins could potentiate the effects of temsirolimus; this hypothesis should be tested further in future prospective trials.
In summary, this study demonstrates that the treatment benefit of temsirolimus over interferon is associated with increases in serum cholesterol. This analysis, however, is .51
Adjusted on-study change and baseline triglyceride only .07 *Hazard ratio (HR) is for comparison of treatment of temsirolimus versus Interferon †Analysis unadjusted (univariate) or adjusted (multivariate) for baseline and on-study change in marker level. Other baseline factors refer to trial prespecified factors: age, sex, geographic region, nephrectomy status, tumor histologic type, time from metastasis to randomization, Karnofsky performance score, and levels of hemoglobin, serum lactate dehydrogenase, and corrected serum calcium.
